ArticleMiddle East journal of digestive diseases2025
Survival Rate in Hepatocellular Carcinoma after Surgery and Its Association with Clinicopathological Factors: A Single-Center Report.
Article in Middle East journal of digestive diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer globally and the third leading cause of cancer-related deaths. Survival rate is a key health indicator that aids in assessing diagnostic and therapeutic approaches. This study aimed to evaluate the survival rate of patients with HCC and identify clinicopathological factors influencing survival in Iran, where data are limited. Methods: This cross-sectional retrospective study examined the medical records of 45 patients with HCC who underwent surgery at Imam Khomeini hospital, Tehran, from 2013 to 2019. Demographic, clinical, and histopathological data were collected, and survival rates were analyzed using the Kaplan-Meier method. Multivariate analysis was performed using Cox regression to identify independent prognostic factors. Results: The mean age of patients was 48.6±18.56 years, with 62.2% being male. The average follow-up period was 34.28 months, with a maximum of 102 months. The median overall survival was 26 months, with 1-year and 3-year survival rates of 66.7% and 46.7%, respectively. Multivariate analysis identified older age, tumor size>5 cm, presence of steatosis, history of recurrence, and non-transplantation treatment as independent risk factors for mortality. Other factors, such as tumor stage, histological subtype, and serum alpha-fetoprotein levels, were not significantly related to survival. Conclusion: Based on the results, mortality in patients with HCC is significantly influenced by factors such as advanced age, larger tumor size (>5 cm), presence of steatosis, prior recurrence, and absence of liver transplantation as a treatment. These findings underscore the limited prognostic value of variables such as tumor stage, histological subtype, and serum AFP levels. Emphasizing the importance of proactive management, regular follow-up of high-risk individuals, and timely detection to facilitate curative interventions appears to be an essential strategy for enhancing survival outcomes in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.